Viking Therapeutics reported Q2 2024 financial results with a net loss of $22.3M and strong cash position of $942M. The company achieved significant progress across its pipeline programs, particularly in obesity and NASH treatments.Key clinical developments include plans to advance VK2735 into Phase 3 for obesity following successful Phase 2 VENTURE study results showing up to 14.7% weight reduction. The oral formulation of VK2735 demonstrated up to 5.3% weight loss in Phase 1, with Phase 2 trial planned for Q4 2024. The Phase 2b VOYAGE study of VK2809 for NASH met both primary and secondary endpoints, showing 63-75% NASH resolution rates.The company completed enrollment in the Phase 1b study of VK0214 for X-ALD with results expected in 2H 2024. Additionally, Viking presented promising preclinical data from its novel amylin agonist program at ADA, with IND filing planned for 2025. R&D expenses increased to $23.8M from $13.9M YoY, reflecting expanded clinical development activities.

Viking Therapeutics reported Q2 2024 financial results with a net loss of $22.3M and strong cash position of $942M. The company achieved significant progress across its pipeline programs, particularly in obesity and NASH treatments.Key clinical developments include plans to advance VK2735 into Phase 3 for obesity following successful Phase 2 VENTURE study results showing up to 14.7% weight reduction. The oral formulation of VK2735 demonstrated up to 5.3% weight loss in Phase 1, with Phase 2 trial planned for Q4 2024. The Phase 2b VOYAGE study of VK2809 for NASH met both primary and secondary endpoints, showing 63-75% NASH resolution rates.The company completed enrollment in the Phase 1b study of VK0214 for X-ALD with results expected in 2H 2024. Additionally, Viking presented promising preclinical data from its novel amylin agonist program at ADA, with IND filing planned for 2025. R&D expenses increased to $23.8M from $13.9M YoY, reflecting expanded clinical development activities.